New hope for targeted breast cancer treatment before surgery

This study is testing if adding a new drug called inavolisib to standard pre-surgery treatments works better for people with a specific type of early-stage, HER2-positive breast cancer that has a PIK3CA gene mutation. About 164 participants will be randomly assigned to receive the standard drugs with or without inavolisib. The main goal is to see if the new combination helps more patients achieve a 'pathological complete response,' meaning no detectable cancer is found in tissue removed during surgery.